What does a plasma phosphorylated tau 217 (p‑tau217) level of 0.42 pg/mL indicate and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Plasma P-Tau217 Level of 0.42 pg/mL: Interpretation and Management

A plasma p-tau217 level of 0.42 pg/mL is extremely low and strongly indicates the absence of Alzheimer's disease amyloid pathology, making AD an unlikely cause of any cognitive symptoms.

Clinical Significance

This value falls well below established cutoffs for amyloid positivity across all major assay platforms. Plasma p-tau217 demonstrates excellent diagnostic accuracy with AUCs of 0.92-0.98 for detecting amyloid pathology 1, performing comparably to CSF testing and amyloid PET imaging.

Interpretation Framework

  • Negative Result: Your patient's value of 0.42 pg/mL is definitively in the amyloid-negative range
  • Diagnostic Performance: In cognitively impaired populations, plasma p-tau217 achieves 82% sensitivity and 86% specificity for detecting amyloid pathology 2
  • Negative Predictive Value: A negative result like this has high NPV, particularly in specialized care settings where the test is recommended 3

Management Recommendations

Pursue alternative diagnoses for cognitive impairment. With this negative biomarker result, focus your diagnostic workup on:

  • Non-AD neurodegenerative diseases: Frontotemporal dementia, Lewy body disease, vascular cognitive impairment
  • Reversible causes: Thyroid dysfunction, B12 deficiency, medication effects, depression
  • Mixed pathologies: Vascular disease, metabolic disorders

When to Consider Confirmatory Testing

You generally do not need confirmatory amyloid PET or CSF testing with a value this low. However, consider confirmation if:

  • Clinical presentation is highly atypical for the suspected alternative diagnosis
  • Patient has advanced chronic kidney disease (eGFR <45 mL/min/1.73 m²), which can falsely elevate p-tau217 levels 4, 5
  • Patient is severely anemic (hemoglobin <12 g/dL in women, <13 g/dL in men), which may affect interpretation 4

Important Caveats

Biological Factors Affecting Interpretation

Check kidney function before finalizing your interpretation. Reduced kidney function associates with elevated plasma p-tau217 concentrations even in patients without AD 5. The optimal cutoffs differ:

  • Standard populations: Cutoffs typically range from 0.5-2.0 pg/mL depending on assay platform
  • CKD patients: May require adjusted cutoffs to maintain diagnostic accuracy 4
  • Obesity (BMI ≥27.5): May also affect optimal cutoff thresholds 4

Age and Cognitive Status Considerations

  • Cognitively unimpaired individuals <65 years: May require alternative cutoffs, though your patient's value would still be negative 6
  • Cognitively impaired patients: The test performs with consistently high accuracy (sensitivity and specificity ≥90%) 6

Clinical Context

This test should only be interpreted within a specialized care setting after comprehensive evaluation including neurological examination, cognitive testing, and laboratory screening for reversible causes 3, 1. The 2025 Alzheimer's Association guidelines emphasize that blood biomarkers are not standalone diagnostic tests but must be integrated into clinical assessment 3.

Two-Step Workflow Option

If you had clinical uncertainty, a two-step approach (plasma p-tau217 followed by confirmatory PET/CSF for positive results) achieves 91% positive predictive value 7. However, with a value of 0.42 pg/mL, you are already at the negative end of the spectrum—no second step is needed.

Assay-Specific Considerations

Confirm which assay platform was used (UGOT Simoa, Roche Elecsys, or C2N %p-tau217 ratio), as cutoffs vary by platform 1. Regardless of platform, 0.42 pg/mL remains well below any established positive threshold.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.